Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer

Abstract

Six or seven months of adjuvant chemotherapy or chemoendocrine therapy improve both the quantity and quality of life for patients with node-positive breast cancer compared with a single short course of perioperative combination chemotherapy.